# Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

> **NCT03197467** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 30 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03197467
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2021-10-30
- **Final completion:** 2023-05-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197467, "Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03197467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*